Bronstein, Gewirtz & Grossman LLC Announces Altimmune, Inc. Investors May Join Class Action!

NEW YORK, NY / ACCESSWIRE / May 12, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, informs investors that a class action lawsuit has been filed against Altimmune, Inc. (“Altimmune” or “the Company”) (NASDAQ:ALT) and certain of its officers.

Class definition:

The purpose of this lawsuit is to recover damages against defendants for alleged violations of the federal securities laws on behalf of all individuals and entities that purchased or otherwise acquired Altimmun securities between December 1, 2023 and April 26, 2024 (including the “Class Period”) have. Such investors are encouraged to join this case by visiting the Company’s website: bgandg.com/ALT.

Case details:

The lawsuit alleges that defendants made materially false and misleading statements about the Company’s business, operations, and prospects throughout the Class Period. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose: (1) Altimmune has pemvidutide’s potential to differentiate itself from competing GLP-1 agonists based on what has been observed The MOMENTUM process overestimates drug efficacy and tolerability results; (2) accordingly, the results of the MOMENTUM trial were less significant to the clinical, commercial, and competitive prospects of pemvidutide than Defendants had led investors to believe; (3) Based on the foregoing, Defendants had overstated Altimmune’s prospects of finding a strategic partner for the development of pemvidutide; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.

What’s next?

A class action lawsuit has already been filed. If you would like to review a copy of the Complaint, you may visit the Company’s website: bgandg.com/ALT or you may contact Peretz Bronstein, Esq. turn around. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Altimmune, you have until July 5, 2024 to ask the Court to appoint you as lead plaintiff. Your ability to share in the recovery does not require that you serve as lead plaintiff.

There are no costs for you

We represent investors in class actions on a contingency fee basis. This means that we will only ask the court to reimburse us for our expenses and attorneys’ fees, usually a percentage of the total recovery, if we are successful.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm representing investors in securities fraud class actions and shareholder derivative litigation. Our company has recovered hundreds of millions of dollars for investors nationwide.

Lawyer advertising. Previous results do not guarantee similar results.

CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller,
332-239-2660 | (email protected)

SOURCE: Bronstein, Gewirtz and Grossman, LLC